2023
Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts
Weiss A, Martínez‐Sáez O, Waks A, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia M, Prat A, Partridge A, Tolaney S, Cejalvo J, Mittendorf E, King T. Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts. Cancer 2023, 129: 1836-1845. PMID: 36951169, DOI: 10.1002/cncr.34750.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerNeoadjuvant chemotherapyUpfront surgeryNodal positivityBreast cancerTumor sizeALND ratesCT1c tumorsTreatment strategiesSmall human epidermal growth factor receptor 2Lymph node dissection ratesReceptor-positive breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Clinical T1-T2Lymph node positiveHER2-positive patientsGrowth factor receptor 2Optimal treatment strategyFactor receptor 2Nodal statusSystemic therapyNode positiveAxillary imagingPositive tumors
2007
Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis
Punglia R, Winer E, Weeks J, Burstein H. Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis. Journal Of Clinical Oncology 2007, 25: 502-502. DOI: 10.1200/jco.2007.25.18_suppl.502.Peer-Reviewed Original ResearchDisease-free survivalOptimal treatment strategyAromatase inhibitorsHazard ratioUnselected womenTreatment strategiesBreast cancerEstrogen receptor-positive breast cancerWt/wt patientsReceptor-positive breast cancerEarly-stage breast cancerAnnual recurrence riskAdjuvant endocrine treatmentEfficacy of tamoxifenPercent of patientsActive tamoxifen metabolitesWT cohortsEndocrine treatmentBIG 1Initial treatmentTamoxifen metabolitesCancer recurrenceUnselected groupMutation carriersPharmacogenomic testing